PTEN is a human gene coding for an enzyme called phosphatase and tensin homolog (PTEN). PTEN in a tumor suppressor gene which prevents mutations from occurring in genetic code. Therefore, mutations in PTEN are prevalent in many malignancies including brain, breast, lung, and prostate cancers.
-
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
Immune therapy approaches are being used in many different solid cancers today including clear cell renal carcinoma (mccRCC) and metastatic prostate adenocarcinoma. Over the past few years i...
Background: Pathologists have long recognized that the interaction between immune and tumour cells is critical in the development and progression of breast cancer. Studies have demonstrated...
Determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Biomarkers have been shown to predict therapy outcome in various types of cancer...
The oncogenic transcription factor c-MYC (MYC) is deregulated, and often overexpressed, in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease,...
The inability of neurons to regenerate damaged axons within the CNS has dire consequences for victims of traumatic or ischemic brain injury and multiple neurodegenerative diseases. Like other...